Sutton Wealth Advisors Inc. Arcus Biosciences, Inc. Transaction History

Sutton Wealth Advisors Inc.

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 Nov 07, 2023	SELL	$15.96 - $23.15 $13,198 - $19,145	-827 Closed	0 $0
Q4 2022 Nov 07, 2023	BUY	$19.7 - $35.71 $98 - $178	5 Added 0.61%	827 $17.1 Million
Q3 2022 Nov 07, 2023	BUY	$23.23 - $30.07 $8,571 - $11,095	369 Added 81.46%	822 $21.5 Million
Q2 2022 Nov 07, 2023	BUY	$17.23 - $37.73 $7,805 - $17,091	453 New	453 $11.5 Million

200

51.5M

236K

141K

Ticker RCUS
Exchange NYSE
Sector Healthcare
Industry Biotechnology
Shares Outstandng 72,160,000
Market Cap $1.12B
Description
Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. Its product pipeline includes, Etrumadenant, a dual A2a/A2b adenosine receptor antagonist, which is in a Phase 1b/2 clinical trial; and Zimberelimab, an anti-PD-1 antibody that is in Phase 1b clinical trial for ...

Get notified when there are updates to the investment portfolio of Sutton Wealth Advisors Inc., based on Form 13F filings with the SEC.

Stay updated on Sutton Wealth Advisors Inc. with notifications on news.